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Abstract 
 
Bismuth ferrite (BFO) harmonic nanoparticles (NPs) display high nonlinear optical efficiency 
and excellent biocompatibility profile which make them attractive for the development of 
diagnostic applications as contrast agents. In this study, we present a general method for the 
functionalization of this material with chemical ligands targeting cancer molecular biomarkers. 
In particular, a conjugation protocol based on click reaction between alkynyl containing 
targeting ligands and poly(ethylene glycol) coated BFO NPs (67.7 nm) displaying surface 
reactive azido groups was developed. Copper-free click reaction allowed fast and efficient 
conjugation of a covalent inhibitor of prolyl-specific endopeptidases to coated BFO NPs. The 
ability of these functionalized nanomaterials (134.2 nm) to act as imaging probes for cancer 
cells was demonstrated by the selective labelling of human lung cancer cells. 
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Introduction 
 
Nanomaterials, and in particular nanoparticles (NPs), are being increasingly developed as 
contrast agents for the imaging of fundamental biological processes. Several types of materials, 
including silica NPs and nanocomposites (Wang et al. 2015), quantum dots (Kairdolf et al. 
2013), carbonaceous nanomaterials (Wen et al. 2015), semiconductor nanotubes and nanosheets 
(Ahmad et al. 2015), upconversion and metal oxide NPs (Erathodiyil et al. 2011; Zhou et al. 
2015) have been widely explored for bioimaging applications. While 
fluorescence/luminescence (Yao et al. 2014; Wolfbeis 2015; Chinen et al. ASAP) and 
plasmonic response (Bardhan et al. 2011) are the most common optical properties used for 
imaging techniques, nonlinear optical response has only been recently demonstrated in a series 
of promising imaging applications. In this context, harmonic nanoparticles (HNPs), which are 
composed by non-centrosymmetric materials presenting a highly efficient nonlinear response, 
can be easily imaged by their second harmonic generation signal in multi-photon imaging 
setups (Bonacina 2012; Cohen 2010; Pantazis et al. 2010; Meyer et al. 2013). In contrast with 
most nanophotonic probes for bioimaging applications which are based on static optical 
properties, HNPs can fully exploit the tuning capabilities offered by new laser sources (from 
400 to 1550 nm). In addition, despite their lower brightness compared to fluorescence imaging 
labels, HNPs present many favorable properties for optical imaging, including the absence of 
photobleaching and blinking (Le Xuan et al. 2008), no specific wavelength dependence 
allowing excitation from UV to IR (Extermann et al. 2009), fully coherent response and narrow 
emission signals (Baumner et al. 2010; Hsieh et al. 2010). These unique features combined in 
a single optical probe have been recently reported for cell, tissue and in vivo imaging 
applications (Čulić-Viskota et al. 2012, Dempsey et al. 2012, Magouroux et al. 2012). 
Various types of HNPs, mainly metal oxide materials, have been produced and characterized, 
such as barium titanate (BaTiO3), iron iodate (Fe(IO3)3), lithium niobate (LiNbO3), potassium 
niobate (KNbO3), potassium titanyl phosphate (KTP) and zinc oxide (ZnO). In a comprehensive 
study, we demonstrated that these nanoparticles display efficient harmonic conversion and low 
cytotoxicity with the exception of ZnO materials (Staedler et al. 2012). More recently, bismuth 
ferrite nanoparticles (BiFeO3, abbreviated as BFO-NPs) were introduced as promising 
nonlinear optical probes due to their very high second harmonic efficiency which was 
demonstrated to be one order of magnitude higher than for standard harmonic nanomaterials 
(Schwung et al. 2014). In addition, we gave evidence for the good biocompatibility of 
PEGylated BFO-NPs (Staedler et al. 2015) and for the ability of BFO-NPs to locally induce 
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DNA damage by deep UV generation (Staedler et al. 2014). In view of the favorable profile of 
these HNPs for bio-imaging applications, their functionalization with targeting entities was 
envisaged for the development of nanoprobes for cancer cells labelling. Different types of 
targeting agents, including antibodies, peptides and small molecules have been conjugated to 
inorganic NPs for the detection of cancer molecular biomarkers. Antibodies offer high affinity 
and selectivity to the resulting conjugates, but may alter the permeability of NPs across the 
vasculature and the blood vessel walls as they considerably increase the size of the NPs 
(Arruebo et al. 2009). Antibody-NPs conjugates may also induce adverse immune response 
over prolonged use. Therefore, surface modification of BFO-NPs with low molecular weight 
targeting ligands appears as an appealing strategy for the detection of cancer cells (Sun et al. 
2006). 
We report herein a functionalization methodology for the conjugation of PEGylated BFO-NPs 
to cancer targeting ligands based on azide-alkyne [3+2] cycloaddition (click reaction), 
catalyzed by copper (I) species (Rostovtsev et al. 2002) or promoted by the use of strained 
cyclooctynes (Sletten et al. 2011). In particular, the cyclic Arg-Gly-Asp (RGD) peptide 
derivative cRGDfK, a ligand for the αvβ3 integrin (Danhier et al. 2012), and a specific inhibitor 
of prolyl-endopeptidases (Juillerat-Jeanneret et al. 2009; Brennen et al. 2012), respectively, 
were covalently associated to the nanoparticles surface for recognition of the cancer cells and 
cancer associated-cells membrane molecular biomarkers. The resulting cancer-targeting NPs 
have been characterized and evaluated for their ability to label human lung cancer cells. 
 
Materials and methods 
 
Chemical syntheses – General conditions 
 
Commercial reagents (Fluka, Aldrich, TCI, Switzerland) were used without further purification. 
Unless special mention, all reactions were performed under argon atmosphere (1 atm). 
Anhydrous solvents were obtained by filtration (Innovative Technology, Oldham, UK). 
Reactions were monitored by TLC (Merck silica gel 60F254 plates, Merck, Darmstadt, 
Germany). Detection was performed by UV light, KMnO4, Ninhydrin or I2. Purifications were 
performed by flash chromatography on silica gel (Merck N° 9385 silica gel 60, 240-400 mesh). 
IR spectra were recorded on a Perkin-Elmer-1420 spectrometer (Perkin-Elmer, Waltham, MA, 
USA). 1H-NMR spectra were recorded on a Bruker ARX-400 spectrometer (400 MHz) (Bruker, 
Billerica, MA, USA). 13C-NMR spectra were recorded on a Bruker ARX-400 spectrometer 
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(100.6 MHz). Chemical shifts are expressed in parts per million (ppm) and coupling constants 
(J) in hertz. Solvents used for NMR spectroscopy are deuterated chloroform (CDCl3, Acros) 
and deuterated methanol (CD3OD, Acros). Mass spectra were obtained on a Nermag R-10-10C 
spectrometer with chemical ionization (NH3) and mode m/z (amu) [% relative base peak 
(100%)] (Nermag, Santa Clara, CA, USA). Semi-preparative HPLC was performed on a Waters 
Autopurification ZQ System equipped with a 2767 Sample Manager, a 2525 Binary Gradient 
Module and a 2996 Photodiode Array Detector, coupled to Waters Micromass ZQ analyzer. 
The HPLC purifications were performed on XTerra Prep RP C18 (19 x 150 mm) columns, 
using reverse-phase conditions (2 to 100% acetonitrile with 0.1% TFA over 20 min). 
Measurements of the dynamic light scattering and zeta potential were obtained using a Malvern 
NanoZ instrument (Malvern Instruments, Malvern, UK). 
 
Synthesis of targeting ligands (Scheme 2) 
 
Synthesis of tert-butyl [(3-oxo-1,2-dihydro-1H-isoindol-5-yl)oxy]acetate (4). 
To a solution of 3 (6.13 mmol, 1.0 g) in CH3SO3H (20 equiv, 7.96 mL) was added methionine 
(1.8 equiv, 11.04 mmol, 1.64 g) and the mixture was stirred at 85 °C for 16 h. After cooling to 
25 °C, cold water (5 °C) was added, and the mixture was maintained at 5 °C for 1 h. The solid 
was recovered by filtration, washed with water containing aqueous 1% HCl, and then dried to 
afford the intermediate phenol (664 mg, 73 %) as a white solid. To a solution of this 
intermediate (11.4 mmol, 1.7 g) in N,N-dimethylformamide (DMF)/ dichloromethane (DCM) 
(1:1, 20 mL), were added tert-butyl bromoacetate (11.97 mmol, 3.11 g, 2.35 mL), Bu4NBr (0.57 
mmol, 184 mg) and 50 % aqueous NaOH (11.97 mmol, 479 mg). The mixture was stirred for 
16 h at 25°C and the product was extracted with DCM (20 mL). The organic layer was dried 
(MgSO4) and concentrated in vacuo. Purification by flash chromatography (petroleum ether 
(PE)/EtOAc 1:1) gave 4 as a white solid (1.88 g, 62 %). ESI-HRMS: calcd for C14H17NO4: 
264.1236; found: 264.1244. 1H-, 13C- NMR and IR spectral description are given in supporting 
information. 
 
Synthesis of (S)-tert-butyl 2-((2-(2-(2-cyanopyrrolidin-1-yl)-2-oxoethyl)-3-oxoisoindolin-5-
yl)oxy)acetate (6). 
1M Lithium bis(trimethylsilyl)amide (LiHMDS) in tetrahydrofuran (THF) (615 µmol, 615 µL) 
was added to a cooled (0 °C) solution of 4 (410 µmol, 107 mg) in THF (1.2 mL). After 30 min, 
a solution of 5 (529 µmol, 115 mg) in THF (1.2 mL) was added dropwise. The mixture was 
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slowly warmed to 25°C and was stirred for 10 h. Completion of the reaction was monitored by 
thin-layer chromatography (TLC) and ESI-MS. Volatiles were removed in vacuo. The crude 
residue was purified by flash chromatography (DCM, then DCM/MeOH 60: 1) to afford 6 as a 
transparent oil (0.120 g, 73 %). ESI-HRMS: calcd for C21H25N3O5: 400.1873, found 400.1886. 
1H-, 13C- NMR and IR spectral description are given in supporting information. 
 
Synthesis of ligand 2 
Compound 6 (1.25 mmol, 500 mg) was added to a suspension of silica (6.25 g) in toluene (25 
mL). The mixture was refluxed for 1.5 h under vigorous stirring. The mixture was diluted in 
DCM/MeOH 4:1 and celite was added. The mixture was filtered. The pad of celite was washed 
with DCM/MeOH 4:1 and the combined filtrates were evaporated under reduced pressure to 
obtain free carboxylic acid intermediate as a white solid (quant.). To this compound (131 µmol, 
45 mg) in DMF (1 mL) were added compound 7 (137 µmol, 60 mg), 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDCI) (222 µmol, 43 mg), 1-hydroxybenzotriazole 
(HOBt) (170.3 µmol, 23 mg) and (iPr)2NEt (393 µmol, 50.8 mg, 65 µL). The reaction mixture 
was stirred for 12 h at 25 °C. DMF was evaporated and the product was purified by flash 
chromatography (DCM/MeOH 25:1) to afford 2 as a colorless oil (98 µmol, 75 mg, 75 %). ESI-
HRMS: calcd. for C42H45N5O9: 764.3295; found: 764.3293. 1H-, 13C- NMR and IR spectral 
description are given in supporting information. 
 
Functionalization of BFO-NPs (Scheme 3) 
 
Functionalization of PEG-BFO NPs with ligand 1 
To a suspension of PEG-BFO NPs (6 mg) in EtOH (1 mL) was added distilled water (2 mL) 
and 1 (4 mg, dissolved in 100 µL of DMF). CuSO4 (2 mg) and sodium ascorbate (2 mg) were 
added and the suspension was ultra-sonicated for 12 h at 40 °C. 1,4,8,11-
Tetraazacyclotetradecane (Cyclam) (10 mg) was added and the suspension was dialyzed against 
a solution of dodecyltrimethylammonium bromide in distilled water (0.1 M, 2 mL) for 24 h 
followed by dialysis against distilled water (3 x 24 h). fNP-1 were concentrated and suspended 
in EtOH (1 mL). 
 
Functionalization of PEG-BFO NPs with ligand 2 
To a suspension of PEG-BFO NPs (5.5 mg) in EtOH (1 mL) were added distilled water (5 mL) 
and 2 (13 µmol, 10 mg, dissolved in 750 µL of DMF). The suspension was ultra-sonicated for 
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12 h at 40 °C. The suspension was washed with toluene (3 x 5 mL) and organic layers were 
washed with water. Combined aqueous layers were evaporated and co-evaporated with toluene 
in vacuo. The resulting fNP-2 were suspended in EtOH (1 mL). 
 
Characterization of functionalized BFO NPs: DLS and zeta potential measurement 
 
A suspension of coated or functionalized NPs (20 µL) was diluted with distilled H2O (1 mL) 
and AcOH (100 µL) was added. The resulting suspension was ultra-sonicated for 5 min and 
washed 3 times with distilled H2O (1 mL). NPs were suspended in distilled water (1 mL) and 
sonicated for 30 min. The sizes and surface charges of the resulting suspensions were analyzed 
with a Malvern NanoZ instrument (Malvern Instruments, Malvern, UK). 
 
Inhibition of human recombinant enzyme by compound 8 
 
The human recombinant enzymes were obtained from: hrDPPIV (Enzo Life Sciences, Lausen, 
Switzerland), hrFAPα (R&D systems, Abingdon, UK) and hrPOP/PREP (Enzo Life Sciences). 
The enzymatic activity was measured in flat bottom 96-well plates (Costar, Corning, NY, USA) 
containing in each well 0.01 µg of the enzymes and 50 µM of substrate (Z-Gly-Pro-AMC for 
hrFAPα and hrPOP, and H-Gly-Pro-AMC for hrDPPIV, both substrates from Bachem) diluted 
in their respective assay buffers (50 mM Tris, 1 M NaCl and 1 mg/mL bovin serum albumin 
(BSA), pH 7.5, for hrFAPα; 50 mM Tris and 1 mg/mL BSA, pH 7.5, for hrPOP; 25 mM Tris 
and 1 mg/mL BSA, pH 8.0 for hrDPPIV; all reagents from Sigma-Aldrich, Buchs, Switzerland). 
The enzyme solutions were incubated for 30 min with increasing concentrations (5, 10, 50, 200, 
500, 1000, 5000 and 10000 nM) of compound 8. Then inhibition was determined by evaluation 
of the residual enzymatic activity: measurement of the fluorescence increase for 1 h at 37°C in 
a fluorescence multi-well plate reader (λex/λem = 360/460 nm, Synergy HT, BioTek, Winooski, 
VT, USA). Experiments were conducted in triplicate wells and repeated twice. IC50 and Ki were 
calculated according to Cer et al (2009). 
 
Cells and cell culture conditions 
 
A549, BEAS-2B, NCI-H596, NCI-H520 cell lines are available from ATCC (American Tissue 
Culture Collection, Manassas, VA, USA). A549 and BEAS-2B cells were grown in Dulbecco's 
Modified Eagle Medium (DMEM) medium containing 4.5 g/L glucose, 10% heat-inactivated 
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fetal calf serum (FCS) and penicillin/streptomycin (all cell culture reagents were obtained from 
Invitrogen, Basel, Switzerland). NCI-H596 cells were grown in complete Roswell Park 
Memorial Institute (RPMI) 1640 medium (Invitrogen) supplemented with 20% FCS and 
penicillin/streptomycin. NCI-H520 cells were grown in RPMI 1640 medium supplemented 
with 10% FCS and penicillin/streptomycin. 
 
Detection of the association of compound 8 with cells  
 
The cells were grown for 48 h in BD Falcon CultureSlides (BD Biosciences, Erembodegem, 
Belgium), then the cell layers were washed with Hank's Balanced Salt Solution (HBSS) at 
37 °C, exposed to 100 µM of compound 8 or to vehicle (dimethyl sulfoxide (DMSO)), 0.5% 
final concentration) in HBSS for 30 min at 37 °C. Cell layers were washed twice with HBSS 
and fixed with 4% formaldehyde in PBS for 30 min at 5 °C. The fixed cell layers were blocked 
for 1h with 1% BSA in PBS (phosphate buffered saline) at room temperature, then washed and 
exposed to horseradish peroxidase (HRP)-conjugated streptavidin (Merck) diluted 1:100 in 
antibody diluent (Dako, Baar, Switzerland). HRP activity was revealed using the DAB+ 
CHROMOGENTM system from Dako, according to the supplier instructions. Finally, the cell 
layers were counterstained with hematoxylin and images were taken using a transmitted light 
microscope (DM IL LED from Leica, Renens, Switzerland) equipped with a digital camera 
(ICC50HD, Leica). 
 
Inhibition of prolyl-oligopeptidase activities in living cells 
 
The cells (50'000 cells/well) were grown for 24 h in flat bottom 96 well plates (Corning), then 
were exposed to increasing concentrations (5, 10 and 20 µM) of compound 8 and to 50 µM of 
Z-Gly-Pro-7-amino-4-methylcoumarin (AMC) (for prolyl-endopeptidase activity) or 50 µM of 
H-Gly-Pro-AMC (for prolyl-exopeptidase activity) (Bachem, Vionnaz, Switzerland). 
Fluorescence increase was measured for 1 h at 37 °C in a fluorescence multi-well plate reader 
(Synergy HT) at λex/λem = 360/460 nm. Experiments were conducted in triplicate wells and 
repeated twice. Means + standard deviations were calculated. 
 
Detection of the association between compound 8 and cells 
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The cells were grown for 48 h in BD Falcon CultureSlides (BD Biosciences), then the cell 
layers were exposed to vehicle (DMSO) or to compound 8 at the indicated time and 
concentrations in cell medium at 37 °C. After the incubation time, the cell layers were fixed 
with 4% formaldehyde in PBS for 30 min at 5 °C. Fixed cells were then washed with PBS, 
permeabilized 5 min in 0.1% Triton X-100 (Sigma-Aldrich) in PBS, incubated 10 min at 25 °C 
in 3% H2O2 in methanol and blocked 2h with 1% BSA in PBS at 25 °C, then washed and 
exposed for 90 min to HRP-conjugated streptavidin (Merck) diluted 1:100 in antibody diluent 
(Dako). HRP activity was revealed using the DAB+ CHROMOGENTM system from Dako, 
according to the supplier instructions. Finally, the cells were counterstained with hematoxylin 
and images were taken using a transmitted light microscope (DM IL LED from Leica) equipped 
with a digital camera (ICC50HD, Leica). 
 
Multiphoton imaging of the association between fNP-2 and cells 
 
Cells were grown on round-shaped microscope coverslips (BD Falcon) for 24 h in a 24 well 
plate (Corning) then the cell layers were washed with HBSS at 37 °C and exposed to the coated 
and functionalized NPs at indicated concentrations or to vehicle (ethanol, 1% final 
concentration) in 500 µL HBSS for indicated time at 37 °C. The cell layers were washed twice 
with HBSS and fixed in 4 % formaldehyde in PBS for 30 min at 5 °C. After fixation, the cells 
were labelled with fluorescent probes. 
For imaging, a multiphoton inverted microscope (Nikon A1R-MP) coupled with a tunable 
Ti:Sapphire oscillator (Spectra-Physics Mai-Tai, 100 fs, 80 MHz, 700-1000 nm) was used. A 
20× N.A. 0.75 objective was used to focus the excitation laser and to epi-collect the SHG signal 
from the nanoparticles and dye markers fluorescence. Typical average power at the sample: 3 
mW. 
 
Results and discussion 
 
Efficient surface functionalization of BFO NPs is of high importance for bio-imaging 
applications, in particular for targeted imaging of cancer cells and early stage tumors. We 
decided to explore the conjugation of targeting entities by click reaction between PEGylated 
BFO NPs displaying surface reactive azido groups and alkynyl containing ligands designed for 
recognition of molecular cancer biomarkers (Scheme 1). αvβ3 Integrin is a well-established 
target for cancer diagnosis (Desgrosellier et al. 2010) and can be efficiently bound by cyclic 
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RGD peptides and RGD peptidomimetics. Prolyl-oligopeptidases, in particular the serine 
proteases FAPα which exhibits both exopeptidase and endoproteolytic activity, and prolyl-
oligopeptidase (POP) which is restricted to endoproteolytic cleavages, have been associated 
with the development of cancers and other diseases (Brennen et al. 2012; Lawandi et al. 2010). 
Covalent inhibitors based on previously reported N-blocked boroPro inhibitors (Poplawski et 
al. 2013) can thus be developed for the labelling of malignant cells and tumor-associated cells 
expressing these enzymes. 
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Scheme 1 Functionalization of BFO NPs for cancer cells labeling 
 
Our strategy relies on the conjugation of PEGylated BFO NPs with ligands 1 and 2 as model 
compounds for the targeting of αvβ3 integrin and prolyl-specific endopeptidases expressed by 
cancer and tumor-associated cells. 
 
Synthesis of targeting ligands for conjugation to harmonic NPs 
 
Ligand 1 resulted from the coupling of cRGDfK, prepared by solid phase peptide synthesis 
(Borcard et al. 2012), with activated ester of pentynoic acid as previously reported (Passemard 
et al. 2013). Preparation of ligand 2 started by cleavage of the methyl ether from isoindolinone 
3 (prepared according to Powers et al. 2009) followed by subsequent O-alkylation of the 
corresponding phenol with tert-butyl bromoacetate to afford compound 4 in 45 % yield. 
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Deprotonation of the lactam moiety followed by condensation with cyano-proline derivative 5 
(synthesis described in supporting information) delivered the core of the targeting agent (6) in 
73% yield. Further derivatization with a cyclooctyne moiety was performed by coupling with 
compound 7 (synthesis described in supporting information) to provide the targeting ligand 2, 
ready to be conjugated to PEGylated BFO NPs. To assess the targeting ability of this ligand 
toward prolyl-specific endopeptidases in cancer cell lines, functionalization with a biotin label 
was also performed and delivered compound 8. 
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Scheme 2 Synthesis of targeting ligands for further conjugation to harmonic NPs 
 
 
Functionalization of BFO NPs with targeting ligand 1 and 2 
 
Starting suspension of BFO NPs (62.5 wt % in ZrO2 balls, provided by the company FEE 
(Germany)) was first converted into a stock polydisperse suspension at 3.6 mg/mL (particle 
size: 128.8  ± 11.2 nm), and then converted into PEGylated nanoparticles (PEG-BFO NPs, 
particle size: 67.7  ± 5.6 nm), according to a protocol previously described in our group 
(Staedler et al. 2015) (detailed protocol and characterization is provided in supporting 
information). Based on recent efforts toward the development of efficient functionalization 
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pathways for metal oxide NPs (Passemard et al. 2013), PEG-BFO-NPs displaying surface azido 
and amino functionalities were suspended in distilled water and subjected to [3 + 2]-
cycloaddition with ligand 1, in the presence of copper sulfate and sodium ascorbate (Scheme 
3). Ultrasonication for 12 hours followed by removal of copper species by treatment with 
Cyclam and purification by dialysis afforded BFO NPs conjugated to the ligand targeting αvβ3 
integrin (fNP-1). Alternatively, treatment of PEG-BFO NPs with ligand 2 allowed conjugation 
by copper-free click reaction to afford fNP-2, which were purified by simple washing with 
toluene to remove unreacted ligand. 
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Scheme 3 Functionalization of BFO harmonic NPs by click reaction 
 
Surface functionalization of PEG-BFO NPs was monitored by FT-IR (Figure 1). The formation 
of the resulting triazole moieties was evidenced by apparition of a C-N stretching band at 1320 
(fNP-1) and 1390 (fNP-2) cm-1. Presence of the peptide ligand in fNP-1 was indicated by amide 
stretching bands at 1650 and 1570 cm-1, while nitrile stretching band at 2320 cm-1 supported 
conjugation of targeting ligand 2 to PEG-BFO NPs. 
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Fig. 1 FT-IR spectra: PEG-BFO NP (black), fNP-1 (red), fNP-2 (blue) 
 
The coated and functionalized NPs were characterized for their size and surface charge by 
measurement of the mean hydrodynamic diameter (Dynamic Light Scattering, DLS) and zeta 
potential (detailed characterization is provided in supporting information). Upon 
functionalization, the hydrodynamic diameter of harmonic NPs shifted from 67.7 ± 5.6 nm 
(PEG-BFO NP) to 141.8 ± 0 nm for fNP-1 and to 134.2 ± 11.5 nm for fNP-2. The zeta potential 
value increased from -2.3 ± 0.4 mV (PEG-BFO NP) to +17.3 ± 0.3 mV (fNP-1) and +0.7 ± 
0.9 mV (fNP-2). 
 
Targeting ability of functionalized harmonic NPs and cancer cells labelling 
 
The first cellular assays performed with fNP-1 revealed the presence of traces of residual copper 
species which resulted in cytotoxic effects on studied cells. Attempts of additional purification 
were not met with success. Detailed studies were thus carried out on functionalized harmonic 
nanoparticles fNP-2, resulting from copper-free click reaction. 
Compound 8 was first assessed for its ability to inhibit prolyl-endopeptidase activity on the 
most relevant members of the prolyl-oligopeptidase family, both on human recombinant (hr) 
enzymes and on human lung cancer cells extracts (Table 1). Compound 8 was tested on hrPOP 
and hrFAPα, as well as on the prolyl exopeptidase dipeptidyl peptidase IV (hrDPPIV) to 
determine the selectivity toward endo-proteolytic activity. 
While compound 8 inhibited both hrFAP-α and hrPOP with Ki values of 0.055 and 0.12 µM, 
respectively, no significant inhibition was observed for human recombinant DPPIV. This 
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observation suggests the specificity of compound 8 toward oligopeptidases displaying prolyl-
endopeptidase activity. 
 
 hrFAPα hrDPPIV hrPOP 
 IC50 (µM) Ki (µM) IC50 (µM) Ki (µM) IC50 (µM) Ki (µM) 
8 0.315 0.055 > 10 - 0.58 0.12 
Table 1 Kinetic characteristics for the inhibition of prolyl-oligopeptidases by compound 8 
Human recombinant FAP-α (hrFAP-α), DPPIV (hrDPPIV) and POP (hrPOP) were exposed to 
increasing concentrations (5, 10, 50, 200, 500, 1000, 5000 and 10000 nM) of compound 8, then 
to 50 µM of the appropriate substrate (Z-Gly-Pro-AMC for hrFAPα and hrPOP, H-Gly-Pro-
AMC for hrDPPIV) and the residual enzymatic activity was determined. The half maximal 
inhibitory concentration (IC50) and the inhibition constant (Ki) were calculated. 
 
The inhibition by compound 8 of cell-associated prolyl-endopeptidase activities was then 
evaluated on a cancer model composed of the three human A549, NCI-H596 and NCI-H520 
lung-derived carcinoma cancer cells and the human lung-derived non-tumoral BEAS-2B 
epithelial cells (Figure 2A). All cancer cells displayed significant enhanced endo-peptidase 
activity compared to the non-tumoral BEAS-2B cells. Compound 8 inhibited prolyl-
endopeptidase activity only in tumor cells and not in the non-tumoral cells, whereas no 
inhibition of prolyl-exopeptidase activity in these cells was observed (data not shown). In 
addition, when added to living cells, compound 8 associated with lung-derived A549 cancer 
cells, but not with non-tumoral BEAS-2B cells (Figure 2B). 
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Fig. 2 Compound 8 inhibits the prolyl-oligopeptidase activity of human lung cancer cells (A) 
and associates with lung human cancer cells (B) 
A. The human lung-derived A549, NCI-H520 and NCI-H596 cancer cells and non-tumoral 
lung-derived BEAS-2B cells were pre-incubated with 10 µM of compound 8 for 30 min, then 
the residual enzymatic activity was determined using 50 µM of Z-Gly-Pro-AMC and expressed 
as percent of inhibition by compound 8. Exposed cells were compared to cells exposed to 
solvent (DMSO) using a Student’s t-test : ** : p < 0.01; *** : p < 0.001. B. Lung-derived cancer 
cells (A549) and non-tumoral cells (BEAS-2B) (100'000 cells/well) were exposed to 100 µM 
compound 8 for 30min, then the association of this compound with the cells was assessed by 
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adding a peroxidase-conjugated streptavidin. The binding of compound 8 in exposed cells and 
cells exposed to the vehicle (DMSO) was compared. Blue: counterstain with haematoxylin; 
brown spots: compound 3 detected by streptavidin. Magnification: 400x. 
 
Based on these results, the targeted labelling of human lung cancer cells with fNP-2 was 
investigated using one tumoral (NCI-H520) and one non-tumoral (BEAS-2B) lines. PEGylated 
harmonic NPs (PEG-BFO NPs) were considered as negative controls. The cells were exposed 
to fNP-2, then labelled with a fluorescent probe for cell membranes, and the harmonic NPs 
were revealed by detecting their SHG signal (excitation at 790 nm) (Figure 3). 
 
Fig. 3 Cancer cells labelling using fNP-2 
Lung-derived NCI-H520 (tumoral) and BEAS-2B (non-tumoral) cells (100'000 cells/well) were 
exposed for 30 min to 50 µg/mL of PEG-BFO NP, to 50 µg/mL of fNP-2 or to 50 µg/mL of 
fNP-2 after 30min pre-incubation with 100 μM of compound 8 (Competition assay), then the 
cells were fixed and the cell membranes were labelled using the fluorescent probe FM1-43FX 
(red). SHG of NPs was detected by multiphoton microscopy (blue, those associated with cells 
are indicated with white arrows). Magnification: 200x. 
 
17 
 
In order to evaluate the specificity of the targeting, a competition assay was done, in which 
lung-derived NCI-H520 cancer cells were incubated with compound 8 alone prior to being 
exposed to fNP-2. Cells labelled with NPs were counted and the number of cells displaying 
association with the NPs was expressed as the percent ratio of positive cells to total cells in a 
microscopic field (Figure 4). 
 
 
Fig. 4 Quantification of cells labelled with fNP-2 
Human lung-derived NCI-H520 (tumoral, black bars) and BEAS-2B (non-tumoral, grey bars) 
cells were exposed to 25 µg/mL of PEG-BFO NP, to 50 µg/mL of fNP-2 or to 25 µg/mL of 
fNP-2 after 30 min pre-incubation with 100 μM of compound 8 (Comp). The number of labelled 
cells was expressed as the percent of the ratio of cells displaying association with the NPs to 
the total cells in a microscopy field (magnification 200x). The percentages of cells labelled with 
PEG-BFO NP were compared to those of cells labelled with fNP-2, then tumoral cells were 
compared to non-tumoral cells using a Student’s t-test : *p<0.05; ***p < 0.001. 
 
Both cancer cells and non-tumoral cells were labelled with fNP-2, but the number of cancer 
cells associated with fNP-2 was significantly much higher than for non-tumoral cells. 
Moreover, in the competition assay the quantification of the association clearly revealed that 
the binding was target-specific. These results suggest that harmonic BFO NPs can be efficiently 
transformed into labeling nanodevices targeting proteins expressed at the surface of cancer 
cells. 
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Conclusion 
 
Here we present a general approach for the functionalization of imaging NPs with low 
molecular weight tumor-specific targeting agents. In particular, copper-free click reaction 
allows highly efficient conjugation of alkynyl containing ligands to PEGylated BFO NPs 
displaying surface reactive azido groups. The resulting nanoparticles combine imaging 
properties and specific recognition of cancer cell biomarkers offering new modalities for 
improved early cancer diagnosis, a presently unmet need (Zuo et al. 2007). Following the 
demonstration of the potential of BFO-NPs for bio-imaging and selective photointeraction 
(Staedler et al. 2014) and the study of their biological effect (Staedler et al. 2015), the present 
study demonstrate, for the first time, their ability to be converted into targeted imaging 
nanodevices. While the selectivity factor for the labelling of cancer cells vs non-tumoral cells 
need to be improved, the strategy illustrated herein can be easily transferred to other metal oxide 
NPs, thus enlarging the range of detection modalities. In addition, the use of a specific covalent 
inhibitor of cell membrane prolyl endo-peptidases that can be further modified without affecting 
its affinity for the targeted enzymes, appears as an appealing methodology for targeting cancer 
and tumor-associated cells. 
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